Table 3. Clinical and Genetic Characteristics of Published Cases Including Initial Molecular Lesion JAK2 and BCR/ABL in Combination With Molecular Change of JAK2, BCR/ABL or JAK2 and BCR/ABL.

Reference	Initial phenotype	Initial molecular lesion	Phenotype change	Molecular change	Observations
Bee et al, 2010 [24]	PVa	JAK2 and BCR/ABL	CML	JAK2 present when BCR/ABL is treated, and vice versa.	Two clones with clonal dominance.
Payande et al, 2011 [25]	ETa	JAK2 and BCR/ABL	No	No	-
Hummel et al, 2012 [6]	CML	JAK2 and BCR/ABL	PV	High JAK2 allele burden when PV phenotype.	PV phenotype when treated with imatinib.
Darling et al, 2017 [18]	Neutrophilic leukocytosis, basophilia and thrombocytosis	JAK2 and BCR/ABL	No	-	Treated with TKI.
Xu et al, 2014 [26]	CML	BCR/ABL and JAK2	No	-	Two clones? CMR with TKI, persistent JAK2.
Hassan et al, 2015 [27]	CML/MF	BCR/ABL and JAK2	No	-	JAK2 tested in deferred in first sample. Poor control of BCR/ABL with TKI.
Hussein et al, 2008 [17]	CMLb	BCR/ABL and JAK2	No	-	Concurrent lesions at the beginning.
Toogeh et al, 2011[28]	PV	JAK2 homozygous BCR/ABL	-	-	-
Park et al, 2013 [29]	ET	JAK2 and BCR/ABL	None	-	Poor response with hydroxyurea.
	PMF	JAK2 and BCR/ABL	-	-	BCR/ABL controlled with TKI.
Qin et al, 2014 [30]	ET	JAK2 and BCR/ABL	-	-	Diagnosis during pregnancy.
Kramer et al, 2007 [31]	CML	BCR/ABL	MF	JAK2	JAK2 positive tested in deferred in first sample.
Bornhauser et al, 2007 [8]	MF	-	-	BCR/ABL JAK2	BCR/ABL secondary event proved by progenitor colonies analysis.
Campiotti et al, 2009 [32]	CML	BCR/ABL and JAK2	-	-	JAK2 and BCR/ABL controlled with TKI.
Pastore et al, 2013 [33]	CML	BCR/ABL	TE	JAK2	JAK2 positive tested in deferred in first sample.
Cambier et al, 2008 [34]	PV	BCR/ABL and JAK2	-	-	Two clones proved by progenitor colonies analysis.
	CML
Conchon et al, 2008 [35]	MF	BCR/ABL and JAK2	-	-	JAK2 positive when BCR/ABL controlled with TKI.
	CML
Inami et al, 2007 [36]	CMLa	BCR/ABL	PV	JAK2	JAK2 positive tested in deferred in first sample.
Gattenlohner et al, 2009 [37]	CML	BCR/ABL	MDS/MPN	JAK2	JAK2 positive since the beginning.

^aAdditional high WBC/thrombocytosis/erythrocytosis. ^bBone marrow findings of other MPN. WBC: white blood cell; PV: polycythemia vera; PMF: primary myelofibrosis; ET: essential thrombocytosis; CML: chronic myelogenous leukemia; TKI: tyrosine kinase inhibitor; MPN: myeloproliferative neoplasm; MDS: myelodysplastic syndrome; CMR: Complete molecular response.